The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | The potential of MRD as a surrogate marker in randomized trials to accelerate drug approvals
Bruno Paiva, PhD, University of Navarra, Pamplona, Spain, comments on the potential of measurable residual disease (MRD) as a surrogate marker in randomized clinical trials to accelerate drug development and drug approvals in multiple myeloma. Dr Paiva highlights the results of a recent study that identified a correlation between different MRD negativity rates and progression-free survival (PFS) in a data analysis from randomized clinical trials. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
